9-benzyl-2-(4-methylphenyl)-2,6-dihydro[1,2,4]triazolo-[4,3-c]quinazoline-3,5-dione | 1189797-76-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 9-benzyl-2-(4-methylphenyl)-2,6-dihydro[1,2,4]triazolo-[4,3-c]quinazoline-3,5-dione
• 英文别名: 9-Benzyl-2-(4-methylphenyl)-2,6-dihydro[1,2,4]triazolo[4,3-c]quinazoline-3,5-dione；9-benzyl-2-(4-methylphenyl)-6H-[1,2,4]triazolo[4,3-c]quinazoline-3,5-dione
• CAS: 1189797-76-9
• 化学式: C₂₃H₁₈N₄O₂
• 分子量: 382.422
• InChiKey: AHVORQFVDUDBGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  29
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  6-溴-2-(甲硫基)-4(3H)-喹唑啉酮 在 四(三苯基膦)钯 碘 、 三乙胺 、 N,N-二异丙基乙胺 、 间氯过氧苯甲酸 、 三苯基膦 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 85.58h， 生成 9-benzyl-2-(4-methylphenyl)-2,6-dihydro[1,2,4]triazolo-[4,3-c]quinazoline-3,5-dione
  参考文献：
  名称：

  [EN] GABAa RECEPTOR MODULATORS
  [FR] MODULATEURS DES RÉCEPTEURS GABAA

  摘要：

  这项最新的发明涉及具有广谱公式(I)的新化合物，具有镇静、抗惊厥、催眠-催眠和肌肉松弛条件，以及作为GABAA受体调节剂的哺乳动物，包括人类，具有焦虑、催眠和癫痫症状。

  公开号：

  WO2009123537A1

文献信息

• [EN] TRIAZOLOQUINAZOLINONE SYNTHESIS<br/>[FR] SYNTHÈSE DE TRIAZOLOQUINAZOLINONE
  申请人：GABATHER AB

  公开号：WO2019123011A1

  公开（公告）日：2019-06-27

  The invention relates to an improved process for preparing triazoloquinazolinones of Formula (I), including 9-benzyl-2-(4-methylphenyl)-2,6-dihydro[l,2,4]triazolo[4,3-c]quinazoline-3,5-dione, pharmaceutical compositions comprising the compounds of Formula (I), including 9-benzyl-2-(4- methylphenyl)-2,6-dihydro[l,2,4]triazolo[4,3-c]quinazoline-3,5-dione, prepared by the improved process, and methods of treatment using the compounds of Formula (I), including 9-benzyl-2-(4- methylphenyl)-2,6-dihydro[l,2,4]triazolo[4,3-c]quinazoline-3,5-dione, prepared by the improved process.

  该发明涉及一种改进的制备Formula(I)的三唑基喹唑啉酮的方法，包括9-苄基-2-(4-甲基苯基)-2,6-二氢[1,2,4]三唑并[4,3-c]喹唑啉-3,5-二酮，包括Formula(I)化合物的药物组合物，包括通过改进的方法制备的9-苄基-2-(4-甲基苯基)-2,6-二氢[1,2,4]三唑并[4,3-c]喹唑啉-3,5-二酮，以及使用通过改进方法制备的Formula(I)化合物进行治疗的方法。
• GABAA RECEPTOR MODULATORS
  申请人：Nielsen Mogens

  公开号：US20110092525A1

  公开（公告）日：2011-04-21

  The resent invention relates to novel compounds of the general formula (I) having anxiolytic, anticonvulsant, sedative-hypnotic and myorelaxant conditions as well as anxiogenic, somnolytic and convulsant conditions in mammals, including humans, as GABA A receptor modulator.

  本发明涉及具有广泛公式（I）的新化合物，作为GABAA受体调节剂在哺乳动物，包括人类中具有抗焦虑，抗惊厥，镇静催眠和肌肉松弛条件，以及焦虑，催眠和惊厥条件。
• GABAA receptor modulators
  申请人：Nielsen Mogens Peter Cherly

  公开号：US08809355B2

  公开（公告）日：2014-08-19

  The present invention relates to novel compounds of the general formula (I) having anxiolytic, anticonvulsant, sedative-hypnotic and myorelaxant conditions as well as anxiogenic, somnolytic and convulsant conditions in mammals, including humans, as GABAA receptor modulator.

  本发明涉及一种新的化合物，其通式为(I)，在哺乳动物，包括人类中作为GABAA受体调节剂具有抗焦虑、抗癫痫、镇静催眠和肌肉松弛作用，同时具有焦虑、催眠和惊厥等作用。
• Triazoloquinazolinediones as novel high affinity ligands for the benzodiazepine site of GABAA receptors
  作者：Jakob Nilsson、Ritha Gidlöf、Elsebet Østergaard Nielsen、Tommy Liljefors、Mogens Nielsen、Olov Sterner

  DOI：10.1016/j.bmc.2010.11.050

  日期：2011.1

  Based on a pharmacophore model of the benzodiazepine-binding site of GABA(A) receptors, a series of 2-aryl-2,6-dihydro[1,2,4]triazolo[4,3-c]quinazoline-3,5-diones (structure type I) were designed, synthesized, and identified as high-affinity ligands of the binding site. For several compounds, K-i values of around 0.20 nM were determined. They show a structural resemblance with the previously described 2-phenyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones (II) and 2-phenyl-[1,2,4]triazolo[1,5-a]quinoxalin-4(5H)-one (III). The 9-bromo substituted compounds 8a-d were prepared in an 8-step synthesis in an overall yield of approximately 40%, and a library of 9-substituted analogues was prepared by cross-coupling reactions. Compound 8e, 21, 22, and 24 were tested on recombinant rat alpha(1)beta(3)gamma(2), alpha(2)beta(3)gamma(2), alpha(3)beta(3)gamma(2), and alpha(5)beta(3)gamma(2) subtypes, and displayed selectivity for the alpha(1)beta(3)gamma(2) isoform. (C) 2010 Elsevier Ltd. All rights reserved.
• EP3752507A1
  申请人：——

  公开号：EP3752507A1

  公开（公告）日：2020-12-23